Spirooxindole derivatives as emerging scaffolds for antidepressant drug development; A Comprehensive Review

Depression is a multifactorial neuropsychiatric disorder affecting millions worldwide and is associated with monoamine imbalance, neuroinflammation, and impaired neurogenesis. Despite the availability of antidepressants such as SSRIs and TCAs, limitations including delayed onset of action and adverse effects necessitate the development of novel therapeutic agents.

Spiro oxindoles represent a unique class of heterocyclic compounds characterized by a spiro-fused oxindole core. Their structural rigidity and three-dimensional architecture enhance receptor binding affinity and selectivity, making them attractive scaffolds in drug discovery [1,2,16].

Depression is a chronic and debilitating neuropsychiatric disorder characterized by persistent sadness, loss of interest or pleasure (anhedonia), cognitive impairment, and disturbances in sleep and appetite. According to global health estimates, depression is among the leading causes of disability worldwide, significantly contributing to the overall burden of disease. The pathophysiology of depression is complex and multifactorial, involving dysregulation of monoaminergic neurotransmission, neuroinflammation, oxidative stress, hypothalamic–pituitary–adrenal (HPA) axis dysfunction, and impaired neuroplasticity [2,17,20].

Conventional antidepressant therapies, including selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs), primarily target monoamine neurotransmitters such as serotonin, norepinephrine, and dopamine. Although these drugs are widely prescribed, they suffer from several limitations such as delayed onset of therapeutic action, incomplete remission, treatment resistance, and undesirable side effects including weight gain, sexual dysfunction, and sedation. Moreover, approximately one-third of patients fail to respond adequately to first-line antidepressant therapies, highlighting the urgent need for novel therapeutic agents with improved efficacy and safety profiles [1,2].

In recent years, medicinal chemistry has increasingly focused on the development of structurally novel and pharmacologically diverse scaffolds capable of modulating multiple biological targets simultaneously. Among these, spirocyclic compounds—and particularly Spiro oxindole derivatives—have attracted considerable attention due to their unique three-dimensional architecture and wide-ranging biological activities. The Spiro oxindole scaffold is characterized by a rigid bicyclic system in which an oxindole moiety is spiro-fused at the C-3 position to another cyclic framework. This structural motif imparts conformational restriction, enhances binding specificity, and improves pharmacokinetic properties such as metabolic stability and bioavailability [1,16].

Spiro oxindole derivatives are present in numerous natural products and bioactive molecules, many of which exhibit significant pharmacological properties including anticancer, antiviral, antimicrobial, anti-inflammatory, and central nervous system (CNS) activities [5,6,8,9]. The structural resemblance of the oxindole core to indole-based neurotransmitters such as serotonin further supports their potential role in CNS drug discovery. Additionally, the presence of multiple functionalization sites allows extensive structural modification, enabling the fine-tuning of biological activity through rational drug design approaches [2,17].

Recent advances in synthetic chemistry have facilitated the efficient construction of diverse Spiro oxindole frameworks using methodologies such as 1,3-dipolar cycloaddition, multicomponent reactions, and asymmetric organocatalysis [4,10,11,15]. These approaches enable rapid generation of structurally complex molecules with high stereochemical control, which is crucial for biological activity. Furthermore, the incorporation of various substituents at strategic positions on the Spiro oxindole scaffold has been shown to significantly influence pharmacological properties, particularly in the context of CNS activity and antidepressant potential [13,20].

Emerging evidence suggests that Spiro oxindole derivatives can modulate multiple pathways implicated in depression, including monoaminergic signalling, glutamatergic neurotransmission (via NMDA receptor modulation), neurotrophic factor expression (such as brain-derived neurotrophic factor, BDNF), and inflammatory processes [17,19,20]. This multi-target profile offers a significant advantage over traditional single-target antidepressants, potentially leading to faster onset of action and improved therapeutic outcomes.

Given these promising attributes, Spiro oxindole derivatives have emerged as a valuable class of compounds in the search for next-generation antidepressant agents. This review aims to provide a comprehensive overview of the structural features, synthetic strategies, pharmacological mechanisms, and structure–activity relationships of Spiro oxindole derivatives, with a particular emphasis on their potential application in antidepressant drug development.

2. Structural Features of Spiro oxindole

Figure 1: General structure of Spiro oxindole scaffold.

The Spiro oxindole framework consists of an oxindole core fused at the C-3 position with various cyclic systems such as pyrrolidine. This scaffold provides:

• Conformational rigidity
• Defined stereochemistry
• Enhanced receptor interaction
• These features significantly contribute to biological activity and drug-likeness [2,16].

3. Synthetic Strategies

Figure 2: Synthetic approaches to Spiro oxindole derivatives.

Scheme 1: 1,3-Dipolar Cycloaddition

Isatin reacts with sarcosine to generate an azomethine ylide intermediate, which undergoes cycloaddition with chalcones to yield Spiro oxindole derivatives.

Other synthetic approaches include:

• Organocatalytic asymmetric synthesis [10,11]
• Multicomponent reactions [15]
• Metal-catalysed reactions [4]

These methods offer high stereoselectivity and structural diversity [4,10,11,15].

4. Mechanism of Antidepressant Action

Figure 3: Mechanisms involved in antidepressant activity.

Spiro oxindole derivatives may exert antidepressant effects through multiple mechanisms:

4.1 Monoaminergic Modulation

They influence serotonin and dopamine levels, similar to conventional antidepressants [2]. The monoaminergic hypothesis remains one of the most extensively studied frameworks for understanding the pathophysiology of depression. According to this hypothesis, reduced levels or impaired signalling of key monoamine neurotransmitters—primarily serotonin (5-HT), norepinephrine (NE), and dopamine (DA)—play a central role in the development of depressive symptoms. Consequently, modulation of these neurotransmitter systems has been the primary target of most conventional antidepressant therapies [1,2].

Spiro oxindole derivatives have gained increasing attention for their ability to interact with monoaminergic pathways through multiple mechanisms. Structurally, the oxindole core bears resemblance to indole-containing neurotransmitters such as serotonin, which facilitates interaction with serotonergic receptors and transporters. This structural mimicry allows Spiro oxindole-based compounds to function as modulators of serotonin reuptake transporters (SERT), potentially enhancing synaptic serotonin levels and improving mood regulation [2,17].

In addition to serotonergic modulation, Spiro oxindole derivatives have been reported to influence dopaminergic neurotransmission. Dopamine plays a crucial role in motivation, reward processing, and cognitive function—processes that are often impaired in depressive disorders. Certain Spiro oxindole analogues exhibit affinity for dopamine receptors (particularly D2 and D3 subtypes), suggesting their potential to alleviate anhedonia and cognitive deficits associated with depression [17,19]. This dopaminergic activity may provide an advantage over traditional SSRIs, which primarily target serotonin pathways and may not adequately address motivational symptoms.

Furthermore, modulation of the noradrenergic system is another important aspect of the antidepressant activity of Spiro oxindole derivatives. Norepinephrine is involved in regulating alertness, attention, and stress response. Some Spiro oxindole compounds have demonstrated the ability to enhance norepinephrine levels either by inhibiting its reuptake or by modulating adrenergic receptors, thereby contributing to improved mood and cognitive performance [1,20].

4.2 Glutamatergic Pathway

Certain derivatives modulate NMDA receptors, producing rapid antidepressant effects [17]. Among glutamate receptors, the N-methyl-D-aspartate (NMDA) receptor has received considerable attention as a therapeutic target for rapid-acting antidepressants. Overactivation of NMDA receptors lead to increased calcium influx, oxidative stress, and neuronal damage, which contribute to depression-related neurodegeneration. The discovery of ketamine, a non-competitive NMDA receptor antagonist, has revolutionized antidepressant research by demonstrating rapid and sustained antidepressant effects, even in treatment-resistant patients. This has shifted focus toward glutamatergic modulation as a promising strategy for next-generation antidepressant development [17,20].

4.3 Neurotrophic Effects

Upregulation of brain-derived neurotrophic factor (BDNF) promotes neurogenesis [19]. Beyond monoaminergic and glutamatergic mechanisms, increasing attention has been directed toward the role of neurotrophic factors in the pathophysiology and treatment of depression. The neurotrophic hypothesis of depression proposes that reduced levels of neurotrophic factors—particularly brain-derived neurotrophic factor (BDNF)—lead to impaired neurogenesis, synaptic atrophy, and decreased neuronal survival, especially in key brain regions such as the hippocampus and prefrontal cortex [19,20]. Chronic stress, a major risk factor for depression, has been shown to downregulate BDNF expression, resulting in structural and functional alterations in neuronal circuits associated with mood regulation.

BDNF is a critical regulator of neuronal growth, differentiation, and synaptic plasticity. It exerts its effects primarily through activation of the tropomyosin receptor kinase B (TrkB), which triggers downstream signalling cascades including the phosphatidylinositol-3-kinase (PI3K)/Akt pathway, mitogen-activated protein kinase (MAPK)/ERK pathway, and cyclic AMP response element-binding protein (CREB) signalling. These pathways collectively promote neuronal survival, dendritic spine formation, and long-term potentiation (LTP), all of which are essential for maintaining normal cognitive and emotional functions [19].

Spiro oxindole derivatives have demonstrated potential in modulating neurotrophic pathways, thereby contributing to their antidepressant effects. Several studies suggest that these compounds can enhance BDNF expression either directly or indirectly through upstream neurotransmitter systems. For instance, modulation of serotonergic and glutamatergic pathways by Spiro oxindole derivatives may lead to activation of CREB, a transcription factor that regulates BDNF gene expression. This integrated mechanism highlights the interplay between neurotransmitter signalling and neurotrophic regulation in mediating antidepressant effects [17,19].

.4 Anti-inflammatory Activity

Reduction of pro-inflammatory cytokines contributes to improved neuronal function [20]. Accumulating evidence over the past decade has established a strong link between neuroinflammation and the pathophysiology of depression. Elevated levels of pro-inflammatory cytokines, including tumour necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β), have been consistently observed in patients with major depressive disorder. These inflammatory mediators can alter neurotransmitter metabolism, disrupt synaptic function, and impair neuroplasticity, ultimately contributing to the onset and progression of depressive symptoms [20].

Chronic inflammation is known to affect multiple neurobiological systems. One key mechanism involves the activation of microglial cells in the brain, which leads to the release of cytokines and reactive oxygen species (ROS). This neuroinflammatory environment not only damages neuronal structures but also interferes with monoaminergic neurotransmission by increasing the metabolism of tryptophan via the kynurenine pathway. This reduces serotonin availability and generates neurotoxic metabolites such as quinolinic acid, further exacerbating depressive pathology [17,20].

Spiro oxindole derivatives have shown promising anti-inflammatory properties, which may significantly contribute to their antidepressant effects. These compounds are capable of modulating inflammatory signalling pathways and reducing the production of pro-inflammatory cytokines. For instance, several Spiro oxindole analogues have demonstrated inhibitory effects on nuclear factor kappa B (NF-κB), a key transcription factor that regulates the expression of inflammatory mediators. By suppressing NF-κB activation, these compounds can attenuate the inflammatory cascade and protect neuronal integrity [5,20].

In addition to NF-κB inhibition, Spiro oxindole derivatives may influence other intracellular pathways such as the mitogen-activated protein kinase (MAPK) pathway, which plays a critical role in inflammation and stress response. Modulation of MAPK signalling can lead to reduced cytokine production and improved neuronal survival. Furthermore, these compounds may enhance the activity of antioxidant defence systems, thereby reduce oxidative stress and prevent inflammation-induced neuronal damage [19,20].

Another important aspect of the anti-inflammatory mechanism is its interaction with neurotrophic signalling. Inflammatory cytokines are known to suppress BDNF expression, leading to impaired neurogenesis and synaptic plasticity. By reducing inflammatory burden, Spiro oxindole derivatives may indirectly restore BDNF levels and promote neuronal repair. This dual action—anti-inflammatory and neurotrophic—provides a synergistic effect that enhances overall antidepressant efficacy [19].

5. Structure–Activity Relationship (SAR)

Figure 4: SAR of Spiro oxindole derivatives.

Key observations include:

• Substitution at C-3 significantly affects activity [8]
• Electron-withdrawing groups enhance potency [20]
• N-alkylation improves lipophilicity and BBB penetration [17]
• Ring size and stereochemistry influence receptor binding [13]

These findings highlight the importance of rational design in optimizing antidepressant activity.

6. Pharmacological Evaluation

Figure 5: In vivo evaluation models.

Antidepressant activity is evaluated using:

• Forced Swim Test (FST)
• Tail Suspension Test (TST)
• Chronic Unpredictable Mild Stress (CUMS) model

These models assess behavioural changes such as immobility time and anhedonia [18].

7. Drug Design Strategy

4Figure 6: Drug discovery pipeline.